The cost-effectiveness of prophylaxis with valaciclovir in the management of cytomegalovirus after renal transplantation

European Journal of Health Economics

Volumn 6, Issue 2, 2005, Pages 172-182

  Legendre, Christophe ^a   Beard, Stephen M ^b   Crochard, Anne ^c   Lebranchu, Yvon ^d   Pouteil Noble, Claire ^e   Richter, Anke ^b   Durand Zaleski, Isabelle ^f  

^a SAINT LOUIS HOSPITAL   (France)

^b RTI HEALTH SOLUTIONS   (United States)

^c GLAXOSMITHKLINE   (France)

^d CHU BRETONNEAU   (France)

^e CENTRE HOSPITALIER LYON SUD   (France)

^f ANAES   (France)

Author keywords

Cytomegalovirus; Economics; Kidney transplantation; Prevention; Valaciclovir

Indexed keywords

VALACICLOVIR;

ANTIBIOTIC PROPHYLAXIS; ARTICLE; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; CYTOMEGALOVIRUS INFECTION; DRUG COST; DRUG EFFICACY; EVIDENCE BASED MEDICINE; HEALTH SURVEY; HIGH RISK PATIENT; INFECTION PREVENTION; INFECTION RISK; KIDNEY TRANSPLANTATION; MEDICAL DECISION MAKING; MEDICAL INFORMATION; PATIENT MONITORING; PRIORITY JOURNAL; RISK ASSESSMENT;

ACYCLOVIR; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; KIDNEY TRANSPLANTATION; VALINE;

EID: 21344464051     PISSN: 16187598     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10198-004-0275-9     Document Type: Article

References (18)

1. Das A (2003) Related cytomegalovirus infection solid organ transplantation economic implications. Pharmacoeconomics 21:467-475
2. Khoshnevis M, Tyring SK (2002) Cytomegalovirus infections. Dermatol Clin 20:291-299
3. Lopez-Rocafort L, Brennan DC (2001) Current review of cytomegalovirus in renal transplantation. Minerva Urol Nefrol 53:145-158
4. Mauskopf JA, Richter A, Annemans L, Maclaine G (2000) Cost-effectiveness model of cytomegalovirus management strategies in renal transplantation. Comparing valaciclovir prophylaxis with current practice. Pharmacoeconomics 18:239-251
5. Tsevat J, Snydman DR, Pauker SG, Durand-Zaleski I, Werner BG, Levey AS (1991) Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis. Transplantation 52:259-265
6. Richter A, Beard SM (2002) Questionnaire-based survey of current French clinical practice related to CMV Infection following renal transpantation. Final report. GSK data on file
7. Brennan DC, Garlock KA, Lippmann BA (1997) Control of cytomegalovirus-associated morbidity in renal transplant patients using intensive monitoring and either preemptive or deferred therapy. J Am Soc Nephrol 8:118-125
8. Lowance D, Neumayer HH, Legendre CM (1999) Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study group. N Engl J Med 340:1462-1470
9. Kletzmayr J, Kreuzwieser E, Watkins-Riedel T (2000) Long-term oral ganciclovir prophylaxis for prevention of cytomegalovirus infection and disease in cytomegalovirus high-risk renal transplant recipients. Transplantation 70:1174-1180
10. Flechner SM, Avery RK, Fisher R (1998) A randomized prospective controlled trial of oral acyclovir versus oral ganciclovir for cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Transplantation 66:1682-1688
11. Brennan DC, Garlock KA, Singer GG (1997) Prophylactic oral ganciclovir compared with deferred therapy for control of cytomegalovirus in renal transplant recipients. Transplantation 64:1843-1846
12. Jung C, Engelmann E, Borner K, Offerman G (2001) Preemptive oral ganciclovir therapy versus. prophylaxis to prevent symptomatic CMV infection after kidney transplantation. Transplant Proc 33:30621-30623
13. Schneeberger H, Aydemir S, Muller R, Illner WD, Pfeiffer M, Theodorakis J, Zanker B, Land W (2000) Hyperimmunoglobulin prophylaxis, monitoring and preemptive ganciclovir treatment eliminate the risk of CMV infection to improve patient and renal allograft survival. Transplant Int 13 [Suppl 1]:S354-S358
14. Ahsan N, Holman MJ, Sonderbye L, Langhoff E, Yang HC (1998) Oral ganciclovir in the prevention of cytomegalovirus infection in postkidney transplant "CMV at risk" recipients: a controlled, comparative study of two regimens (750 mg Bid and 500 mg Bid). Transplant Proc 30:1393-1385
15. Geddes CC, Church CC, Collidge T, McCruden EA, Gillespie G, Matthews E, Hainmueller A, Briggs JD (2003) Management of cytomegalovirus infection by weekly surveillance after renal transplant: analysis of cost, rejection and renal function. Nephrol Dial Transplant 18:1891-1898
16. Legendre CM, Norman DJ, Keating MR, Maclaine GD, Grant DM (2000) Valaciclovir prophylaxis of cytomegalovirus infection and disease in renal transplantation: an economic evaluation. Transplantation 70:1463-1468
17. Yango A, Morrissey P, Zanabli A, Beaulieu J, Shemin D, Dworkin L, Monaco A, Gohh R (2003) Comparative study of prophylactic oral ganciclovir and valacyclovir in high-risk kidney transplant recipients. Nephrol Dial Transplant 18:809-813
18. Reischig T, Opatrny K Jr, Bouda M, Treska V, Jindra P, Svecova M (2002) A randomized prospective controlled trial of oral ganciclovir versus oral valacyclovir for prophylaxis of cytomegalovirus disease after renal transplantation. Transplant Int 15:615-622